Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.

Antimicrobial Agents and Chemotherapy
Sarah HarmanRobin J Shattock

Abstract

Topical blockade of the gp41 fusogenic protein of HIV-1 is one possible strategy by which microbicides could prevent HIV transmission, working early against infection, by inhibiting viral entry into host cells. In this study, we examined the potential of gp41 fusion inhibitors (FIs) as candidate anti-HIV microbicides. Preclinical evaluation of four FIs, C34, T20, T1249, and L'644, was performed using cellular and ex vivo genital and colorectal tissue explant models. Increased and sustained activity was detected for L'644, a cholesterol-derivatized version of C34, relative to the other FIs. The higher potency of L'644 was further increased with sustained exposure of cells or tissue to the compound. The activity of L'644 was not affected by biological fluids, and the compound was still active when tissue explants were treated after viral exposure. L'644 was also more active than other FIs against a viral escape mutant resistant to reverse transcriptase inhibitors (RTIs), demonstrating the potential of L'644 to be included as part of a multiactive antiretroviral (ARV) combination-based microbicide. These data support the further development of L'644 for microbicide application.

References

Jul 11, 1986·Science·S GartnerM Popovic
Sep 1, 1981·The Journal of Cell Biology·S Banks-Schlegel, H Green
May 6, 1999·European Journal of Immunology·C LapentaS Fais
Aug 3, 1999·American Journal of Epidemiology·E VittinghoffS P Buchbinder
Jan 9, 2001·Annals of Nutrition & Metabolism·M C RousseauJ Delmont
Mar 10, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·C BrionesV Soriano
Mar 10, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S DuweC Kücherer
May 5, 2001·BMJ : British Medical Journal·UNKNOWN UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance
Aug 9, 2002·The New England Journal of Medicine·Susan J LittleDouglas D Richman
Oct 25, 2002·International Journal of STD & AIDS·Seth C KalichmanJames Austin
Apr 12, 2003·AIDS Research and Human Retroviruses·Thomas J KetasJohn P Moore
Nov 25, 2003·Blood·Stuart G TurvilleAnthony L Cunningham
Mar 31, 2004·Lancet·Robin Shattock, Suniti Solomon
Apr 14, 2004·The Journal of Experimental Medicine·Qinxue HuRobin J Shattock
Apr 2, 2005·Nature Reviews. Molecular Cell Biology·Eleonora CandiGerry Melino
Jun 22, 2005·The Journal of Experimental Medicine·Karin LoréRichard A Koup
Oct 20, 2005·The Journal of Infectious Diseases·Minnie JohnBetsy C Herold
Mar 17, 2006·Nature Reviews. Microbiology·Leonid Margolis, Robin Shattock
Oct 9, 2007·The Journal of Infectious Diseases·Sarju PatelMarla J Keller
Oct 16, 2007·The Journal of Investigative Dermatology·Carien M Niessen
Dec 11, 2007·Trends in Molecular Medicine·John A McGrath, Jouni Uitto
Jul 24, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ronald S VeazeyJohn P Moore

❮ Previous
Next ❯

Citations

Dec 12, 2012·Current HIV/AIDS Reports·Charlene S Dezzutti, Florian Hladik
Nov 6, 2013·Antiviral Research·Lisa C RohanLin Wang
Oct 4, 2012·Current Opinion in HIV and AIDS·Ian McGowan
Jan 28, 2014·The Journal of Antimicrobial Chemotherapy·Marcelo T AugustoNuno C Santos
Apr 20, 2014·Journal of the American Society for Mass Spectrometry·Jeremy A BarryDavid C Muddiman
Nov 26, 2013·Expert Opinion on Drug Delivery·Ian McGowan
Sep 18, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Rute NunesJosé das Neves
Jan 16, 2013·Biotechnology Advances·Santi M MandalOctavio L Franco
Nov 5, 2015·Journal of the International AIDS Society·Charlene S Dezzutti
Jun 26, 2018·AIDS Research and Human Retroviruses·Rhonda M BrandIan McGowan
Sep 4, 2020·Scientific Reports·María J GomaraIsabel Haro
Jun 4, 2020·Pharmaceutics·Elena Sánchez-LópezMaría José Gómara
Oct 1, 2018·Advanced Therapeutics·Burcin YavuzDavid L Kaplan
Apr 4, 2021·Vaccines·Carolina HerreraRobin J Shattock
Jul 14, 2021·Bioconjugate Chemistry·Maria J GómaraIsabel Haro

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.